MTTI Highlights Promising One-Year Follow-Up on EBTATE Treatment of Neuroendocrine Cancer Patients Without Amino Acid Infusion

WEST CHESTER, Pa.--(BUSINESS WIRE)-- Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) without amino acid pretreatment. EBTATE’s safety, biodistribution, and dosimetry in a crossover randomized protocol in patients (N=10) with and without amino acids were published in Clinical Nuclear Medicine.¹

The kidney is sensitive to radiation. Peptide receptor radionuclide therapy (PRRT) dosing is constrained by potential kidney toxicity. A 4-hour long amino acid cocktail infusion reduces renal absorbed radiation dose, with significant side effects like nausea, vomiting and hyperkalemia. The Evans blue moiety in EBTATE binds to serum albumin, extending in vivo circulatory half-life and residence time, reducing renal uptake and hence making amino acid infusion unnecessary.

Professor Zhaohui Zhu, MD, principal investigator, commented, “Our results showed that administration of EBTATE without amino acid infusion had acceptable kidney radiation absorbed dose and residence time. One month after EBTATE, there were no significant changes in creatinine, blood urea nitrogen (BUN), and glomerular filtration rate (GFR). None of the patients had nephrotoxicity of any grade. Furthermore, a recent one-year follow-up showed creatine and BUN of all patients stayed within normal limits. EBTATE administration appears to be safe without amino acid infusion.”

Chris Pak, President & CEO of MTTI commented, “Amino acid infusion impacts quality of life, access to care, patient compliance to treatment and overall treatment costs. The benefits of EBTATE treatment without amino acids are clear. We expect EBTATE trials in small cell lung cancer, NET, and nasopharyngeal cancers to show the same benefit.”

Molecular Targeting Technologies, Inc. (MTTI). MTTI is a privately held, venture-backed, clinical-stage biotech company developing next-generation targeted radiotherapeutics for rare cancers with high unmet needs. MTTI is committed to building value by translating innovative radiopharmaceuticals to improve human health and reduce healthcare costs. MTTI is orchestrating multiple clinical trials. For more information: www.evathera.com; Contact: Chris Pak, Email: cpak@mtarget.com

* Jiang Y, Liu Q, Wang G, et al. . Evaluation of Safety, Biodistribution and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue ¹⁷⁷Lu-DOTA-EB-TATE (EBTATE) with and without Amino Acid Infusion. Clin Nucl Med 18 Apr 2023, 48(6):e289-e293

View source version on businesswire.com: https://www.businesswire.com/news/home/20230621096789/en/